The island of Skarpeid rose from the North Sea like the spine of a drowned animal, its granite cliffs scarred by centuries of wind and salt. The ferry from the mainland took three hours, and Elias Voss spent most of the journey standing at the stern, watching the wake churn the gray water into ribbons of white foam. He had not slept well since his meeting with Linnea Dahl. The key she had given him felt heavier than its physical weight, as though it were made of something denser than brass—guilt, perhaps, or obligation, or the accumulated silence of seven people who had died without anyone noticing the pattern.
The ferry docked at the island's only town, a settlement called Åkvåg that clung to the harbor like a colony of barnacles. It was a place that had been dying slowly for decades, its fishing fleet reduced to a handful of boats, its young people drawn away to the mainland cities. The buildings were painted in the traditional Valdorian colors—ochre, rust red, deep blue—but the paint was peeling, and many of the windows were dark. A single main street curved along the waterfront, lined with a grocery store, a post office, a church with a steeple that listed slightly to the east, and a café that advertised "Fresh Pastries Daily" in letters so faded they were barely legible.
Voss walked the length of the street twice before he found the storage facility. It was located behind the old fish processing plant, a windowless concrete building with a corrugated metal roof and a sign that read "Skarpeid Sikkerhetslager — Discretion Guaranteed." The facility was unmanned, secured by a keypad entry system that looked at least fifteen years old. Voss entered the code Linnea had given him—her daughter's birth date, she had said, a detail that had struck Voss as unbearably sad—and the door clicked open with a sound like a bone snapping.
The interior was cold and smelled of damp concrete and mildew. Fluorescent lights flickered to life as he entered, illuminating a long corridor lined with metal storage units, each marked with a number. Unit 47 was at the end of the corridor, tucked into a corner where the light did not quite reach. Voss inserted the key into the padlock and turned it. The lock resisted for a moment, as if reluctant to surrender its secrets, and then opened with a soft click.
Inside the unit, there was a single cardboard box, sealed with packing tape that had yellowed with age. Voss lifted the box and carried it into the corridor, where the light was better. He opened it carefully, the way he had once opened manuscripts in the monastery library, with the reverence of someone who understood that some objects carried more than their physical weight.
The box contained what Linnea had promised: a thick folder of research data, printed spreadsheets filled with numbers and notations, correspondence between Dahl and OmniCure's executive committee, and a USB drive that presumably contained digital copies of the same materials. Voss flipped through the papers, his eyes scanning the columns of data with the practiced efficiency of an actuary. The numbers told a story that the published studies had concealed—a clear, statistically significant increase in adverse events among patients with the CYP2C9 variant, a signal that should have triggered additional investigation but had instead been buried in a footnote.
At the bottom of the box, beneath the research materials, Voss found something unexpected: a photograph. It showed a group of people at what appeared to be a corporate retreat, standing in front of a mountainside lodge. Someone had circled two faces in red ink. One was Linnea Dahl, younger and smiling, her eyes bright with the enthusiasm of a woman who still believed that science could change the world. The other was a man Voss did not recognize—tall, sandy-haired, with the slightly uncomfortable posture of someone who did not enjoy having his picture taken. On the back of the photograph, in Linnea's handwriting, were the words: "Magnus Helle. Siste kjente bilde. Skarpeid, 2018." Last known photograph. Skarpeid, 2018.
Voss studied the man's face for a long moment. Magnus Helle. The junior researcher who had helped Linnea access the raw data. The man who had believed her when she said something was wrong. The man who had been erased from existence.
He put the photograph in his pocket, closed the box, and carried it out of the storage facility. The sky had darkened while he was inside, the gray clouds thickening into a bruised purple that promised more rain. He needed to find somewhere to review the materials in detail, somewhere private where he could work without being observed.
The café with the faded sign was still open. Voss carried the box inside and ordered a cup of coffee from a tired-looking woman who did not seem surprised by the appearance of a stranger with a cardboard box on a weekday afternoon. Tourists came to Skarpeid occasionally, she told him without being asked, mostly hikers and birdwatchers, though the season was late for both. Voss took his coffee to a table in the corner, where the window overlooked the harbor and the gray sea beyond, and began to read.
—
In Kvelborg, two hundred kilometers to the south, Klara Myhre was staring at an anonymous email that had arrived in her inbox at 4:47 that morning.
She had been a journalist for fifteen years, first at the Valdorian News Service, then at the financial daily Kapital, and now at Aftenposten, where she had built a reputation for investigative pieces that made powerful people uncomfortable. She had exposed corruption in municipal governments, fraud in the fishing industry, and human rights violations in the Valdorian prison system. But she had never received an email quite like this one.
The email was brief, written in the careful, precise language of someone who had chosen every word with deliberation:
"Dear Ms. Myhre. I am writing to you because I have evidence of what I believe to be a systematic pattern of medical murder occurring at Solberg Assisted Living Facilities across northern Valdoria. Seven elderly patients have died within one month of being prescribed Cardizine, a drug manufactured by OmniCure Pharmaceuticals. These deaths have been certified as natural cardiac events, but statistical analysis suggests otherwise. I have attached a summary of the relevant data. If you are interested in investigating further, please reply to this address. I will contact you with additional information. — A concerned observer."
The attachment was a PDF containing a detailed analysis of the seven deaths, complete with dates, patient demographics, prescribing physicians, and a statistical calculation showing the probability of the clustering occurring by chance. The analysis was methodical, rigorous, and utterly convincing. It was also, Klara realized after reading it twice, the work of someone who understood not just statistics but the specific language of insurance claims—the terminology, the procedural references, the actuarial methodology.
She sat at her desk in the Aftenposten newsroom, the morning light filtering through the tall windows and casting long shadows across the floor. Around her, the newsroom was coming to life, reporters typing at their keyboards, editors conferring over layouts, coffee cups accumulating on every available surface. Klara ignored all of it, her attention fixed on the email and its implications.
Cardizine. OmniCure. Solberg Assisted Living. These were not obscure names. OmniCure was one of the largest pharmaceutical companies in Valdoria, a cornerstone of the national economy. Solberg operated sixteen assisted living facilities across the country, caring for thousands of elderly patients. Cardizine was one of the most prescribed heart medications in Europe. If what the anonymous source claimed was true, it would be the biggest story Klara had ever investigated.
She picked up her phone and called the number for the Valdorian National Pathology Institute. The call was routed through three different departments before she reached someone who could answer her questions.
"This is Klara Myhre from Aftenposten. I'm calling about the retention protocols for biological samples from assisted living facilities. Specifically, blood samples taken during autopsies of elderly patients."
The voice on the other end belonged to a woman who sounded young and uncertain. "I'm not sure I can discuss our protocols with the press. You'd need to submit a formal request through our communications office."
"I understand. I'm not asking for anything sensitive. I'm just trying to confirm standard procedure. After an autopsy is completed, how long are blood samples retained before destruction?"
There was a pause, the sound of fingers tapping on a keyboard. "Standard protocol mandates destruction of biological samples thirty days after the final autopsy report is filed, unless a hold is placed by a court order or an active police investigation."
"And if samples are not destroyed within that thirty-day window? If, hypothetically, a destruction order was entered but never executed?"
Another pause, longer this time. "That would be a procedural irregularity. It happens occasionally—staffing issues, backlog, administrative errors. But it's not common."
"Thank you," Klara said, and hung up before the young woman could ask any questions of her own.
She sat back in her chair and stared at the email again. The anonymous source had known about the thirty-day retention protocol. He had known that the samples might still exist. He had known exactly what questions to ask and how to find the answers. Whoever he was, he was not an amateur.
Klara began to type a response:
"To the concerned observer. I am interested. Tell me more. — K.M."
She sent the email and waited, watching the screen as if it might yield additional information through sheer force of will. Outside, the rain that had been falling on Kvelborg for eleven days showed no sign of stopping.
—
On Skarpeid, the rain arrived just as Voss finished his first cup of coffee.
He had been reading for nearly two hours, working through Linnea Dahl's research with the systematic attention to detail that had made him one of NordStar Mutual's most effective adjusters. The data was complex—pharmacological analyses, genetic sequencing results, statistical models that required all of his actuarial training to interpret—but the central finding was clear. Cardizine, when administered to patients with a specific mutation in the CYP2C9 gene, produced a metabolite that functioned as a powerful anticoagulant. In patients over seventy, particularly those with pre-existing cardiovascular conditions, this anticoagulant effect could cause fatal internal bleeding that mimicked cardiac arrest.
The clinical trials had detected this signal. Linnea's research demonstrated that clearly. But the signal had been systematically excluded from the published results, buried under layers of statistical manipulation and selective reporting. The drug had been approved on the basis of incomplete data, and OmniCure had known about the risk from the beginning.
But knowing about the risk was one thing. Deliberately administering the drug to vulnerable patients in order to conceal that risk was something else entirely. Voss needed more than statistical probability to prove intentional harm. He needed evidence that someone at OmniCure—or someone connected to OmniCure—had deliberately targeted patients with the genetic variant and prescribed Cardizine knowing it would kill them.
He needed to find Torben Malling, the physician who had prescribed Cardizine to all seven victims. And he needed to find Magnus Helle, the researcher who had vanished five years ago and might hold the key to proving what OmniCure had done.
The café owner approached his table with a fresh pot of coffee. "You've been here a while," she said, refilling his cup. "Are you a researcher?"
"Something like that," Voss said. "I'm looking for someone who used to live on the island. A man named Magnus Helle. He would have moved here around 2018."
The woman's expression shifted, a flicker of something that might have been recognition, quickly suppressed. "I don't know anyone by that name."
"I have a photograph. He was a researcher. Tall, sandy hair. He might have come here with his family—a wife and a daughter."
"I said I don't know him."
Voss studied the woman with the same attention he had once applied to illuminated manuscripts, looking for the meaning hidden beneath the surface of the text. Her denial had been too quick, too flat. She was lying. But why?
"I'm not trying to cause any trouble," Voss said. "I'm trying to prevent it. The man I'm looking for may have information that could save lives. If you know where he is, or how I can reach him, I would be grateful for your help."
The woman set down the coffee pot with a clatter that was louder than necessary. "I've lived on this island my whole life. I've learned that strangers asking questions usually bring trouble with them. I don't know your Magnus Helle, and if I did, I wouldn't tell you where to find him. That's just how it is here."
She walked away before Voss could respond, disappearing through a door into the kitchen. Voss stared after her for a moment, then turned back to the papers spread across his table. The interaction had confirmed something important: Magnus Helle was on Skarpeid. Someone was protecting him.
The rain had intensified outside, hammering against the café windows with the force of a storm that had been building for days. Voss gathered the papers back into the box and stood up, his mind already working through the next steps. He needed to find Helle before OmniCure did—because if he had found the pattern, and if Linnea had known where to look, then it was only a matter of time before someone else connected the same dots.
—
The response to Klara Myhre's email arrived at 11:23 that morning.
"Dear Ms. Myhre. Thank you for your interest. I cannot reveal my identity at this time, but I can provide additional documentation. The seven deaths I described share a common physician: Dr. Torben Malling, who was involved in the original Cardizine clinical trials. I believe Dr. Malling is deliberately prescribing Cardizine to patients with a specific genetic variant that makes the drug lethal. The Solberg facilities are being used as a convenient venue for what amounts to a human experiment designed to eliminate evidence of Cardizine's dangers. I have attached Dr. Malling's prescription records for the past three years, obtained through the Valdorian Prescription Monitoring Program. You will see that his prescribing patterns are anomalous compared to other physicians at Solberg facilities. — A concerned observer."
Klara opened the attachment and found a spreadsheet showing prescription data for Torben Malling. The data showed that Malling had prescribed Cardizine to forty-three patients at Solberg facilities over the past three years. Of those forty-three, seven had died within one month of the prescription. The other thirty-six had survived—but the spreadsheet included a note indicating that genetic testing was required to determine which patients carried the CYP2C9 variant. Without that testing, it was impossible to know how many of the survivors had simply been lucky enough not to have the mutation.
She picked up her phone and called the Solberg corporate office in Kvelborg.
"This is Klara Myhre from Aftenposten. I'm calling to request information about Dr. Torben Malling, who provides services at several of your facilities. Specifically, I'm interested in his prescribing practices for Cardizine and his role in patient care decisions."
The corporate communications director, a man named Ulrik Foss who sounded as though he had been expecting this call for years, responded with practiced smoothness. "Dr. Malling is a respected physician who has provided excellent care to our residents. His prescribing practices are entirely consistent with current medical guidelines. I'm not aware of any concerns regarding his work."
"I have data suggesting that seven patients died within one month of being prescribed Cardizine by Dr. Malling. That seems like a concern."
There was a pause. When Foss spoke again, his voice had hardened. "I would caution you against making allegations based on incomplete data. Cardizine is a widely prescribed medication with an excellent safety record. The patients you're referring to were elderly, with significant pre-existing conditions. Their deaths were tragic but not unexpected. If you publish unsubstantiated claims, OmniCure and Solberg will pursue all available legal remedies."
"Are you threatening me, Mr. Foss?"
"I'm advising you. There's a difference."
Klara hung up and stared at her phone. The call had confirmed what the anonymous source had implied: someone was trying to suppress information about the deaths. Whether that someone was protecting a killer or simply protecting a corporate reputation remained to be seen.
She opened her email and began to compose a message to her editor.
—
The storm hit Skarpeid at dusk.
Voss had checked into the island's only guesthouse, a ramshackle building near the harbor that smelled of salt and old timber. The owner, a taciturn man with a wooden leg and a collection of maritime artifacts that filled every available surface, had given him a room on the second floor with a view of the sea. Voss had spent the afternoon reviewing Linnea's research, cross-referencing it with the prescription records he had obtained from the Valdorian Prescription Monitoring Program, and building a timeline of the seven deaths.
The timeline was damning. Each death had occurred within twenty-one to twenty-eight days of the Cardizine prescription. Each patient had been at least seventy-five years old. Each death had been certified as natural by Torben Malling, the same physician who had prescribed the drug. And each death had been processed by a different insurance adjuster, ensuring that no single person would see the pattern—except for Elias Voss, who saw patterns the way other people saw colors.
As darkness fell over the island, Voss decided to take a walk. The storm had passed, leaving behind a sky that was clearing to reveal a scattering of stars. The streets of Åkvåg were empty, the residents retreated behind their closed doors and curtained windows. Voss walked along the waterfront, past the fish processing plant and the storage facility, past the church with its leaning steeple, until he reached the edge of town.
The road continued beyond the last streetlight, climbing into the hills that formed the island's interior. Voss followed it, his footsteps echoing on the wet pavement. The air was cold and clean, tasting of salt and pine and something else—something that might have been the memory of snow.
He walked for nearly an hour before he saw the house.
It was set back from the road, half-hidden behind a stand of wind-bent trees. A single light burned in one of the windows, a warm yellow glow that seemed to beckon him forward. The house was small, built of gray stone with a slate roof, and it looked as though it had been standing on that hillside for centuries. A wooden fence surrounded the property, and a mailbox at the gate bore a name painted in white letters: "H. Eriksen."
Not Helle. Eriksen. A pseudonym, perhaps, or the name of a wife or a relative. Voss opened the gate and walked up the path to the front door. He knocked once, twice, and waited.
The door opened a crack, revealing a sliver of a face. A woman, middle-aged, with wary eyes and a mouth set in a firm line.
"What do you want?" she asked.
"I'm looking for Magnus Helle," Voss said. "My name is Elias Voss. Linnea Dahl sent me."
The woman's expression did not change, but something shifted in her eyes—a flicker of recognition, quickly suppressed. "I don't know anyone by that name."
"I understand why you would say that. But I'm not here to cause trouble. I'm here because seven people are dead, and Magnus may be the only person who can help me prove why."
The door opened wider. The woman stood in the doorway, studying Voss with an intensity that reminded him of Linnea Dahl's gaze in the bar—the look of someone who had learned to trust no one and was not about to start now.
"Linnea sent you?" she asked.
"She gave me the key to her storage unit on Skarpeid. She told me about the research. She told me about Magnus."
The woman was silent for a long moment. Then she stepped aside and gestured for Voss to enter.
The interior of the house was warm and cluttered, filled with books and papers and the detritus of a life lived in seclusion. A fire burned in the hearth, casting dancing shadows across the walls. In a chair by the fire, wrapped in a wool blanket despite the warmth of the room, sat a man Voss recognized from the photograph. He was thinner now, his sandy hair turned gray, his face lined with the exhaustion of someone who had been hiding for too long.
"You found me," Magnus Helle said, his voice barely above a whisper. "I've been waiting five years for someone to find me."
"I'm sorry it took so long," Voss said.
Helle gestured for him to sit. "Tell me everything. Tell me about the seven people who died. Tell me about Linnea. Tell me what OmniCure has done."
Voss sat down across from the dying fire and began to speak. He told Helle about the pattern he had discovered, about Linnea's research, about Torben Malling and the Solberg facilities and the blood samples that should have been destroyed but had not been. He spoke for a long time, the words flowing out of him like water from a spring that had been dammed too long.
When he finished, Helle was silent for a moment. Then he reached beneath his blanket and produced a small notebook, its pages filled with cramped handwriting.
"I've been waiting for this," Helle said. "I've been documenting everything. Names, dates, internal communications, meeting minutes. When Linnea was discredited, I knew I would be next. So I copied everything I could find—every document, every email, every piece of data that showed what OmniCure knew and when they knew it. I've been waiting for someone to come who could use it."
He held out the notebook to Voss.
"Take it. It's everything you need. But be careful. The people who did this—they're not just protecting a drug. They're protecting billions of euros. They've already killed seven people to keep this secret. They won't hesitate to kill again."
Voss took the notebook, feeling its weight settle into his hands like the weight of the key Linnea had given him, like the weight of the photograph he still carried in his pocket, like the weight of all the silences he had learned to read in fourteen years of monastic life.
Outside, the wind was rising again, and somewhere in the darkness of the island, a door was opening that could never be closed.
No comments yet. Be the first to comment!